Apimeds Pharmaceuticals US (APUS) vs Mustang Bio (MBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Apimeds Pharmaceuticals US is the larger company by market cap ($3.0 million vs $2.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APUS | MBIO |
|---|---|---|
| Share price | $1.60 | $0.3541 |
| Market cap | $2.96M | $2.69M |
| 1-day change | -8.05% | -4.30% |
| YTD return | -90.24% | — |
| 1-year return | -92.98% | — |
| EPS (TTM) | $-12.69 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-6.00M | $-1.92M |
| 52-week high | $59.70 | $1.43 |
| 52-week low | $1.51 | $0.35 |
| Distance from 52-week high | -97.32% | -75.24% |
| Average volume | 3.73M | 33.87K |
| Shares outstanding | 1.85M | 6.74M |
| Employees | — | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apimeds Pharmaceuticals US
APUS stock →Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure.
Health Care · Biotechnology: Pharmaceutical Preparations
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
APUS vs MBIO FAQ
Which is bigger, Apimeds Pharmaceuticals US or Mustang Bio?
Apimeds Pharmaceuticals US (APUS) is larger, with a market capitalization of $2.96M compared with $2.69M for Mustang Bio (MBIO).
Are Apimeds Pharmaceuticals US and Mustang Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.